Powered by

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug

Apr 07, 2021 - GlobeNewswire

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to . The firm is investigating possible securities fraud and certain investors may have valuable claims.

Visit: Contact An Attorney Now:                                               844-916-0895 FibroGen, Inc. (NASDAQ: FGEN) Investigation: The investigation is focused on FibroGen’s presentation of false data of roxadustat to...